Abstract: An antibody solution containing (1) an antibody or a labelled antibody, (2) albumin, and (3) an azo dye containing naphthalenesulfonic acid in its structure and a method for stabilizing an antibody or a labelled antibody comprising adding albumin and an azo dye containing naphthalenesulfonic acid in its structure to a solution of an antibody or a labelled antibody are disclosed.

Abstract: A suppository comprising pranoprofen is disclosed. The suppository has analgesic or anti-inflammatory effects. Since pranoprofen is administered away from gastrointestinal tracts, application of the suppository is not accompanied by side effects such as peptic ulcer, bleeding in constipation, and diarrhea. It is particularly suitable for patients with disorders in digestive organs and infant patients. Pranoprofen is released constantly over a extended period of time.

Abstract: A plaster comprising pranoprofen, a hydrophilic or hydrophobic base component, and an absorbefacient is disclosed. The plaster is effective for curing arthritis deformans, muscle ache, distention after external injuries, and aches. Since pranoprofen is administered away from gastrointestinal tracts, application of the plaster is not accompanied by side effects such as peptic ulcer, bleeding in constipation, and diarrhea. It can release pranoprofen constantly over a extended period of time.

Abstract: A sustained-release pranoprofen preparation is disclosed. The preparation comprises an effective amount of pranoprofen and one or more sustained-release components selected from the group consisting of oily components, water-soluble components, water-insoluble components, and intestinally soluble components. It controls release of pranoprofen and lowers the maximum pranoprofen concentration in blood, maintaining its concentration in blood at a certain level for a long period of time. It reduces risks of side effects and can effectively treat diseases with dosing once or twice a day.

Abstract: A diclofenac sodium preparation comprising a rapidly soluble component including an active ingredient consisting essentially of diclofenac sodium, and an enteric component including an active ingredient consisting essentially of diclofenac sodium and an enteric coating therefor provides prolonged action when the enteric coating is formed from a mixture comprising 100 parts by weight of a methacrylic acid-methyl methacrylate copolymer, 3-40 parts by weight of a glycerin fatty acid ester, and 1-150 parts by weight of talc.